Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed intermediate rhabdomyosarcoma. - Phase II study of VAC2.2/VI therapy for patients with newly diagnosed intermediate rhabdomyosarcoma.

Hosono Ako0 个研究点目标入组 40 人开始时间: 2019年3月27日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Histologically confirmed newly diagnosed rhabdomyosarcoma (RMS), meeting criteria for intermediate.
•2) Age younger than 30 years old.
•3) Initiation of chemotherapy within 42 days after pathological diagnosis.
•4) No prior history of malignancy.
•5) ECOG 0-2 (>=16 years old) or Lansky 50-100% (< 16 years old)
•6) Patients must have sufficient organ function.
•7) All patients and/or their parents or legal guardians must sign a written informed consent.

•1) patients with synchronous or metachronous concomitant malignancies
•2) patients with Charcot-Marie-Tooth disease or varicella
•3) patients with uncontrollable complications
•Interstitial pneumonia, pulmonary fibrosis, severe emphysema
•Uncontrollable diabetes mellitus
•Uncontrollable hypertension
•Severe electrocardiogram abnormality or clinically significant heart disease(heart failure, myocardial infarction, angina pectoris)
•Liver failure, cirrhosis
•Renal failure
•4) patients with contraindication of drugs used in this study
•5) Female patients who are pregnant or breastfeeding mother or patients considering pregnancy
•6) Patients with any other inappropriate condition judged by physician

发起方

Hosono Ako